Literature DB >> 1357527

Evidence for global regulatory control of pilus expression in Escherichia coli by Lrp and DNA methylation: model building based on analysis of pap.

M W van der Woude1, B A Braaten, D A Low.   

Abstract

Pyelonephritis-associated pilus (Pap) expression is regulated by a phase variation control mechanism involving PapB, Papl, catabolite activator protein (CAP), leucine-responsive regulatory protein (Lrp) and deoxyadenosine methylase (Dam). Lrp and Papl bind to a specific non-methylated pap regulatory DNA region containing the sequence 'GATC' and facilitate the formation of an active transcriptional complex. Evidence indicates that binding of Lrp and Papl to this region inhibits methylation of the GATC site by Dam. However, if this GATC site is first methylated by Dam, binding of Lrp and Papl is inhibited. These events lead to the formation of two different pap methylation states characteristic of active (ON) and inactive (OFF) pap transcription states. The fae (K88), daa (F1845) and sfa (S) pilus operons share conserved 'GATC-box' domains with pap and may be subject to a similar regulatory control mechanism involving Lrp and DNA methylation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357527     DOI: 10.1111/j.1365-2958.1992.tb01418.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  33 in total

1.  NmeSI restriction-modification system identified by representational difference analysis of a hypervirulent Neisseria meningitidis strain.

Authors:  A Bart; Y Pannekoek; J Dankert; A van der Ende
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Phase and antigenic variation in bacteria.

Authors:  Marjan W van der Woude; Andreas J Bäumler
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

3.  What does it take to stick around? Molecular insights into biofilm formation by uropathogenic Escherichia coli.

Authors:  Maria Hadjifrangiskou; Scott J Hultgren
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

4.  The UbiI (VisC) Aerobic Ubiquinone Synthase Is Required for Expression of Type 1 Pili, Biofilm Formation, and Pathogenesis in Uropathogenic Escherichia coli.

Authors:  Kyle A Floyd; Courtney A Mitchell; Allison R Eberly; Spencer J Colling; Ellisa W Zhang; William DePas; Matthew R Chapman; Matthew Conover; Bridget R Rogers; Scott J Hultgren; Maria Hadjifrangiskou
Journal:  J Bacteriol       Date:  2016-09-09       Impact factor: 3.490

5.  Induction of Chitin-Binding Proteins during the Specific Attachment of the Marine Bacterium Vibrio harveyi to Chitin.

Authors:  M T Montgomery; D L Kirchman
Journal:  Appl Environ Microbiol       Date:  1994-12       Impact factor: 4.792

Review 6.  The leucine-responsive regulatory protein, a global regulator of metabolism in Escherichia coli.

Authors:  J M Calvo; R G Matthews
Journal:  Microbiol Rev       Date:  1994-09

7.  In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA.

Authors:  Brian J Haugen; Shahaireen Pellett; Peter Redford; Holly L Hamilton; Paula L Roesch; Rodney A Welch
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

8.  The leucine-responsive regulatory protein, Lrp, activates transcription of the fim operon in Salmonella enterica serovar typhimurium via the fimZ regulatory gene.

Authors:  Kirsty A McFarland; Sacha Lucchini; Jay C D Hinton; Charles J Dorman
Journal:  J Bacteriol       Date:  2007-11-02       Impact factor: 3.490

9.  Specific binding of PapI to Lrp-pap DNA complexes.

Authors:  L S Kaltenbach; B A Braaten; D A Low
Journal:  J Bacteriol       Date:  1995-11       Impact factor: 3.490

10.  Identification and transcriptional analysis of the Escherichia coli htrE operon which is homologous to pap and related pilin operons.

Authors:  S Raina; D Missiakas; L Baird; S Kumar; C Georgopoulos
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.